Missing: Bright Angel Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Bright Angel Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Latest Bright Angel Therapeutics News
Apr 15, 2019
Bright Angel: New hope against fungal resistance How Bright Angel's HSP90 inhibitor could block antifungal resistance 3:45 PM Share PDF Bright Angel is tackling antifungal resistance at its root with inhibitors of Hsp90 and other stress response factors, unlike competitors that are developing compounds against known or new pathways where resistance can still emerge. Resistance to the three approved classes of antifungal agents -- azoles, polyenes and echinocandins -- is a growing problem, yet most compounds in development trod the same biological pathways as those classes. According to Bright Angel Therapeutics Inc. co-founder and CSO Leah Cowen, fungal and human proteins, such as Hsp90, share a high degree of homology, raising the potential for toxicity that hampers the development of new targets. Cowen also is a professor of molecular genetics at the University of Toronto. In a series of papers between 2005 and 2018, Cowen and the late Susan Lindquist reported that Hsp90 and other fungal proteins at the nexus of stress responses promoted drug tolerance and resistance. Lindquist was a director at the Whitehead Institute for Biomedical Research and Cowen was... Read the full 787 word article User Sign in
Bright Angel Therapeutics Frequently Asked Questions (FAQ)
When was Bright Angel Therapeutics founded?
Bright Angel Therapeutics was founded in 2017.
Where is Bright Angel Therapeutics's headquarters?
Bright Angel Therapeutics's headquarters is located at Toronto.
What is Bright Angel Therapeutics's latest funding round?
Bright Angel Therapeutics's latest funding round is Seed VC - II.
Who are the investors of Bright Angel Therapeutics?
Investors of Bright Angel Therapeutics include Lumira Ventures, Viva Biotech, Toronto Innovation Acceleration Partners and Schrodinger.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.